₹221.46
▲ +4.34 +2.00%
17 Jul 2026
NSE Listed
ESM 2Bafna Pharmaceuticals Ltd. (BAFNAPH)
20-day avg volume: 9K shares
- Revenue grew 78% YoY.
- Company is loss-making at the latest annual result.
- Stock trades at a high P/E of 187.
| Metric | Sept 2018 | Jun 2019 | Sept 2019 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹9 Cr | ₹7 Cr | ₹12 Cr | ₹39 Cr | ₹35 Cr | ₹35 Cr | ₹38 Cr | ₹42 Cr |
| EBITDA | ₹-1 Cr | ₹-4 Cr | ₹-1 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹1 Cr | ₹2 Cr |
| Net Profit | ₹-1 Cr | ₹-2 Cr | ₹-1 Cr | ₹1 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr |
| EPS | — | — | — | 0.55 | 1.43 | 1.32 | 0.78 | 1.16 |
| Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹179 Cr | ₹187 Cr | ₹144 Cr | ₹87 Cr | ₹66 Cr | ₹79 Cr | ₹44 Cr | ₹43 Cr |
| EBITDA | ₹17 Cr | ₹16 Cr | ₹22 Cr | ₹-2 Cr | ₹-9 Cr | ₹-8 Cr | ₹-16 Cr | ₹-2 Cr |
| Net Profit | ₹4 Cr | ₹1 Cr | ₹6 Cr | ₹-14 Cr | ₹-19 Cr | ₹-17 Cr | ₹-19 Cr | ₹-25 Cr |
| EPS | 2.14 | 0.75 | 3.3 | -8.8 | -10.43 | -9.24 | -11.48 | -15.52 |
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹178 Cr | ₹138 Cr | ₹119 Cr | ₹71 Cr | ₹130 Cr | ₹148 Cr | ₹153 Cr | ₹176 Cr |
| Total Liabilities | ₹136 Cr | ₹101 Cr | ₹101 Cr | ₹20 Cr | ₹56 Cr | ₹67 Cr | ₹68 Cr | ₹79 Cr |
| Equity | ₹42 Cr | ₹37 Cr | ₹19 Cr | ₹51 Cr | ₹73 Cr | ₹81 Cr | ₹85 Cr | ₹96 Cr |
| Total Debt | — | — | — | — | ₹23 Cr | ₹24 Cr | ₹28 Cr | ₹37 Cr |
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹-1 Cr | ₹-7 Cr | ₹-2 Cr | ₹-34 Cr | ₹5 Cr | ₹9 Cr | ₹22 Cr | ₹15 Cr |
| Investing | ₹-5 Cr | ₹38 Cr | ₹15 Cr | ₹33 Cr | ₹-7 Cr | ₹-15 Cr | ₹-21 Cr | ₹-22 Cr |
| Financing | ₹6 Cr | ₹-31 Cr | ₹-14 Cr | ₹7 Cr | ₹10 Cr | ₹-84,54,000 Cr | ₹1 Cr | ₹6 Cr |
| Free Cash Flow | ₹-1 Cr | ₹-7 Cr | ₹-2 Cr | ₹-34 Cr | ₹-3 Cr | ₹-6 Cr | ₹27,62,000 Cr | ₹-10 Cr |
Healthcare · Drug Manufacturers - Specialty & Generic
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences LLP.
www.bafnapharma.com ↗As of 2026-03-31
Quarterly — figures in %. Latest 12 quarters.
| Period | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 90% | 88.7% | 88.4% | 88.3% | 88.3% | 88.3% | 88.3% | 75% | 75% | 75% | 75% | 75% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 8.5% | 9.3% | 9.3% | 9.3% | 9.3% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 10% | 11.3% | 11.6% | 11.7% | 11.7% | 11.7% | 11.7% | 16.5% | 15.7% | 15.7% | 15.7% | 15.7% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 6,992 | 7,354 | 7,367 | 7,539 | 7,391 | 7,295 | 7,214 | 7,142 | 7,283 | 7,572 | 7,119 | 6,928 |
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
| Name | Category | Stake | Shares |
|---|---|---|---|
| Srjr Lifesciences Llp | Shareholding of Promoter and Promoter Group | 74.6% | 1.76 Cr |
| Alpana Mundra | Public Shareholding | 3.3% | 7,69,151 |
| M7 Global Fund Pcc-aerion | Public Shareholding | 3.2% | 7,60,059 |
| M7 Global Fund Pcc - Cell Dewcap Fund | Public Shareholding | 3.1% | 7,37,158 |
| Monarch Networth Finserve Private Limited | Public Shareholding | 1.4% | 3,18,254 |
| Guttikonda Vara Lakshmi | Public Shareholding | 1.3% | 3,04,223 |
| P Paras Bafna | Shareholding of Promoter and Promoter Group | 0.2% | 50,000 |
| Navin Bafna | Shareholding of Promoter and Promoter Group | 0.2% | 42,015 |
| Mahaveer Chand Bafna | Shareholding of Promoter and Promoter Group | 0% | 6,338 |
| Sasikala Bafna | Shareholding of Promoter and Promoter Group | 0% | 1,844 |
| Amri Bai Bafna | Shareholding of Promoter and Promoter Group | 0% | 1,989 |
| Paras Bafna | Shareholding of Promoter and Promoter Group | 0% | 49 |
| Chetna Bafna | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Mahaveer Chand Bafna Huf | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| P Paras Bafna | 0 | 0% | 2026-03-31 |
| Navin Bafna | 0 | 0% | 2026-03-31 |
| Mahaveer Chand Bafna | 0 | 0% | 2026-03-31 |
| Sasikala Bafna | 0 | 0% | 2026-03-31 |
| Paras Bafna | 0 | 0% | 2026-03-31 |
| Chetna Bafna | 0 | 0% | 2026-03-31 |
| Mahaveer Chand Bafna Huf | 0 | 0% | 2026-03-31 |
| Srjr Lifesciences Llp | 0 | 0% | 2026-03-31 |
| Amri Bai Bafna | 0 | 0% | 2026-03-31 |
| M7 Global Fund Pcc-aerion | 0 | 0% | 2026-03-31 |
| M7 Global Fund Pcc - Cell Dewcap Fund | 0 | 0% | 2026-03-31 |
| Alpana Mundra | 0 | 0% | 2026-03-31 |
| Name | Designation | Year |
|---|---|---|
| Shanmugam Hemalatha | E D & Wholetime Director | 2025 |
| Vinayak Dinesh Dendukuri | ED / WTD | 2025 |
| Upendar Mekala Reddy | Non-Exec & Non-Independent Dir | 2025 |
| Ravichandran Chitra | Chairman & Independent Directo | 2025 |
| A Mohanachandran | Company Sec. & Compli. Officer | 2025 |
| Akilapriya Chandrashekar Raju | Non Executive Director | 2025 |
| Palamadai Krishnan Sundaresan | Independent Non Exe. Director | 2025 |
| Segment | Revenue | Share |
|---|---|---|
| Manufacturing and trading of pharma | ₹0 Cr | — |
| Region | Revenue | Share |
|---|---|---|
| INDIA | ₹41 Cr | 63.8% |
| ASIA | ₹14 Cr | 21.8% |
| AFRICA | ₹1 Cr | 2.3% |
| UK | ₹8 Cr | 12.1% |
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 40 | 24 | 24 |
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 2 | 0 | 2 |
| 2025 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 | 0 |
25 recent disclosure(s)
1 disclosure(s)
📍 Bafna Towers New No 68, Old No 299 Thambu Chetty St, Chennai, Tamil Nadu, 600001
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search